Domestic anti-PD-1 therapy! Jiahe biogeptanolimab listing application by the State Drug Administration to treat peripheral T-cell lymphoma (PTCL)

Jiahe Biopharmaceuticals ( ) is a biopharmaceutical company focused on the development and commercialization of innovative and quasi-commercialized oncology and immunodeficiency therapiesRecently, the company announced that its new mono-anti-candidate drug () has been approved by the State Drug Administration () for the treatment of peripheral cell lymphomaA humanized monoclonal antibody that Jiahe Bio developed to target immune cells restores the immune system's ability to recognize and kill cancer cells by selectively blocking the double ligand (and)Phase critical clinical trials for a variety of tumors are currently under way in ChinaIt is worth mentioning that Jiahe Bio is the first biopharmaceutical company in China to treat monotoresisThe prognosis of recurrent or refractive patients has great unmet clinical needs worldwideNeither in China nor in the United States has yet been approved for treatment of the diseaseAt the end of this year, the annual meeting of the American Cancer Research Conference, Jiahe Biology, released data on important studies to treat the incurability of relapseThis is a multicenter, open-label, one-arm clinical trial that evaluates efficacy and safety in the treatment of relapse or refractoryThe study recruited patients from research centers across ChinaThe primary study endpoint seiswells objective mitigation rate () secondary study endpoints include mitigation duration () disease control rate () non-progressive survival () total survival () to mitigation time () safety and immunogenicityThe main research endpoint is assessed by the Independent Imaging Assessment Committee () on the basis of standardsThe study showed significant efficacy in treating patients with relapse or refractive disorder: the main subtypes assessed were able to benefit from negative intercellular lymphoma, and subjects who had previously failed treatment with sidabenamine were still remissionedThe safety characteristics of patients treated in the study are similar to similar to similar to similar products, mainly manifested in immunocortic adverse events () through effective management of symptomatic treatment, suspension or discontinuation of administration, and corticosteroid hormonesMonotophos had a significant benefit risk ratio in the patient population() Original origin: Jiahe Biology.